For Research Use Only. Not for human or veterinary use.
PT-141 is listed for legitimate laboratory and research procurement. This 99%+ research-use product is available in 1 listed specification. Review product codes, storage guidance and COA status, then request a wholesale quotation. Published COA documentation is available for selected specifications.
Volume discounts are available for larger purchasing plans. Please contact us for a quotation.
Delivery includedUsually within 7 days after dispatch
Quality resolutionRefund or replacement when approved
24/7 contactWholesale assistance on WhatsApp
Product profile
About PT-141
"Bremelanotide (formerly PT-141) is a synthetic cyclic heptapeptide and a stabilized derivative of α-melanocyte-stimulating hormone (α-MSH), acting as a melanocortin receptor agonist. Its core mechanism involves activating MC3R and MC4R in the central nervous system, which promotes dopamine release in the medial preoptic area of the hypothalamus, thereby modulating neural pathways associated with sexual desire. Bremelanotide is structurally related to the earlier developed Melanotan-II (MT-II).
The compound received FDA approval in 2019 under the brand name Vyleesi®, for a specific indication (see below). It is administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity, with a recommended dose of 1.75 mg."
Main functions
"1.Improves Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women: Two pivotal Phase III trials demonstrated that bremelanotide significantly improves sexual desire and reduces related distress compared to placebo in premenopausal women with HSDD. Its high affinity for MC4R is thought to promote dopamine release, though the exact mechanism for improving sexual desire is not fully understood.
2.Explored for Erectile Dysfunction: Early studies with an intranasal formulation of PT-141 showed statistically significant erectile responses in healthy men and sildenafil-responsive ED patients, typically occurring about 30 minutes after dosing. However, due to variable bioavailability of the intranasal route, the FDA-approved formulation is an injectable.
3.Explored for Social Cognition in Autism: A study conducted by the University of Sydney investigated the potential of PT-141 nasal spray to improve social cognition (e.g., eye gaze, emotion recognition) in autistic individuals. This research remains at an early exploratory stage."
Recommended audience
"Approved Indication: Premenopausal women diagnosed with acquired, generalized HSDD, characterized by low sexual desire causing marked distress or interpersonal difficulty, and not due to a concurrent medical/psychiatric condition, relationship issues, or medication/substance effects. Bremelanotide is not indicated for use in postmenopausal women, men, or for improving sexual performance.
Research Applications: Participants in clinical studies exploring its potential in male erectile dysfunction, social cognition in autism, and other indications."
Order formatOne box accepted
QuotationConfirmed on WhatsApp
DeliveryShipping and duties included
DocumentationPublished COA or available on request
Research product specification
Product information
PT-141 is listed for legitimate laboratory and research procurement. This 99%+ research-use product is available in 1 listed specification. Review product codes, storage guidance and COA status, then request a wholesale quotation. Published COA documentation is available for selected specifications.
Handling information
Storage guidance
Keep unopened lyophilized products protected from light and moisture; store at 2-8°C short term or -20°C long term. After reconstitution, refrigerate according to product documentation and minimize freeze-thaw cycles.
Customer-first resolution
Report quality concerns within 14 days of delivery
Contact us with the order number, batch details and available photos. Opened products are accepted for review. When a quality claim is approved, you may choose a full refund or replacement shipment.
